Was anyone really backing azathioprine against vitamin R in relapsed ANCA-associated vasculitis? Catch-up on the RCT here.
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
Was anyone really backing azathioprine against vitamin R in relapsed ANCA-associated vasculitis? Catch-up on the RCT here.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) June 3, 2023
✳️10 tweet #NephJC catch-up ✳️
🌟Let’s recap the RITAZAREM trial - a rematch between Rituximab and Azathioprine as the maintenance agent of choice in relapsed ANCA-associated vasculitis.
🌟Have we witnessed the ultimate triumph of Rituximab? pic.twitter.com/HbFKhe6MKc